The type II transforming growth factor-beta receptor as a tumor-suppressor gene
The type II transforming growth factor-beta receptor as a tumor-suppressor gene
复制标题
DOI：
10.1097/00001622-199601000-00009
复制
发表时间：
1996-01-01
影响因子：
3.4
通讯作者：
Willson, James K. V.
中科院分区：
文献类型：
--
作者：
Brattain, Michael G.;Markowitz, Sanford D.;Willson, James K. V.
最近的研究表明：1)转化生长因子-[β]反应的丧失与恶性进展有关，2)维持自分泌阴性转化生长因子-[β]活性是恶性进展的关键障碍，3)复制错误阳性结直肠癌患者RII表达丧失的主要机制是转化生长因子-[β]受体II型（RII）基因多a束突变导致过早产生STOP密码子。Rll在癌症中作用的主要问题是确定Rll缺失机制在非复制错误肿瘤和除结肠癌外的其他类型恶性肿瘤中的外显率。分析Rll丢失的机制可能在临床上用于确定不同类型恶性肿瘤亚群的临床病程，并且可能导致确定某些癌症亚群的新的治疗靶点和方法。
Recent work has shown that: 1) loss of transforming growth factor-[beta] response is associated with malignant progression, 2) maintenance of autocrine negative transforming growth factor-[beta] activity is a key impediment to malignant progression, and 3) the major mechanism for loss of RII expression in replication error-positive colorectal cancer patients is mutation of the poly A tract of the transforming growth factor-[beta] receptor type II (RII) gene resulting in the generation of a premature STOP codon. Major issues for the role of Rll in cancer are identified as the determination of the penetrance of mechanisms of Rll loss in non-replication error tumors and other types of malignancies in addition to colon cancer. Analysis of mechanism of Rll loss may prove to have clinical use in defining the clinical course of subset of different types of malignancies and, in addition, it may result in the identification of new therapeutic targets and approaches for some subsets of cancers.